All In Biotech

Drug Trial Radar · NCT02847442

Efficacy and Safety of Opicapone in Clinical Practice

Efficacy and Safety of Opicapone in Clinical Practice in Parkinson's Disease Patients With Wearing-off Motor Fluctuations

Last checked: Nov 19, 2026Latest source record: Oct 15, 2018 (this record)Source: ClinicalTrials.govMethods & limitations

Completed

Status

Completed

Enrollment

518

Actual

Start

Nov 23, 2016

Primary completion

Jul 4, 2018

Study completion Jul 4, 2018

Sponsor

Lead sponsor
Bial - Portela C S.A.Industry
Sponsor type
Industry
First posted
Jul 28, 2016

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 4
Allocation
Not applicable (single group)
Model
Single group
Masking
None
Primary purpose
Treatment
FDA-regulated drug
No
Who can join
All sexes, from 30 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

The purpose of this study is to evaluate the change in subject's condition according to the Investigator's Global Assessment of Change after three months of treatment with 50 mg opicapone once daily in a heterogeneous patient population reflecting daily clinical practice.

Conditions

  • Parkinson's Disease With Wearing-off Motor Fluctuations

Interventions

  • BIA 9-1067Drug

    Opicapone (BIA 9-1067) 50 mg hard capsules. Oral administration, once daily at bedtime, at least one hour before or after the last daily dose of L-dopa/DDCI.

  • levodopa/dopa decarboxylase inhibitorDrug

    OPC enhances the effects of L-dopa. Hence, it may be necessary to reduce the subject's L-dopa/DDCI dose within the first days or weeks of OPC treatment by extending the dosing intervals and/or reducing the amount of L-dopa/DDCI per dose

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Investigator's Global Assessment of ChangeTime frame: Through study completion, an average of three months

Locations

1 site in 1 country. Site status is shown where the registry gives one.

  • University Hospital Carl Gustav Carus at the TU Dresden, Neurological University Clinic

    Dresden, Germany

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.